Histone deacetylase inhibitors: The epigenetic therapeutics that repress hypoxia-inducible factors

Journal of Biomedicine and Biotechnology

Volumn 2011, Issue , 2011, Pages

  Sang, Nianli ^a   Chen, Shuyang ^a  

^a DREXEL UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLTRANSFERASE; ALPHA TUBULIN; AR 42; CUDC101; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HISTONE DEACETYLASE 5; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE 7; HISTONE DEACETYLASE 8; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MOCETINOSTAT; PANOBINOSTAT; PROTEIN C MYB; PROTEIN P300; ROMIDEPSIN; SIRTUIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VASCULOTROPIN; VORINOSTAT; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; ENDOTHELIAL PAS DOMAIN CONTAINING PROTEIN 1; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; HYPOXIA INDUCIBLE FACTOR 1;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BIPOLAR DISORDER; CANCER CHEMOTHERAPY; CARCINOGENESIS; CELL SURVIVAL; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REPRESSION; EPIGENETICS; EPILEPSY; GENETIC REGULATION; GLUCOSE METABOLISM; HISTONE ACETYLATION; HISTONE UBIQUITINATION; HUMAN; HYDROXYLATION; HYPOXIA; NEOPLASM; OXYGEN SENSING; PROTEIN DEGRADATION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; DRUG ANTAGONISM;

ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; EPIGENOMICS; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1;

EID: 79251576774     PISSN: 11107243     EISSN: 11107251     Source Type: Journal    
DOI: 10.1155/2011/197946     Document Type: Review

References (170)

1. Schwartz D. L., Bankson J. A., Lemos R. Jr., Lai S. Y., Thittai A. K., He Y., Hostetter G., Demeure M. J., Von Hoff D. D., Powis G., Radiosensitization and stromal imaging response correlates for the HIF-1 inhibitor PX-478 given with or without chemotherapy in pancreatic cancer Molecular Cancer Therapeutics 2010 9 7 2057 2067
2. Semenza G. L., Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics Oncogene 2010 29 5 625 634
3. Daponte A., Ioannou M., Mylonis I., Simos G., Minas M., Messinis I. E., Koukoulis G., Prognostic significance of hypoxia-inducible factor 1 alpha(HIF-1alpha) expression in serous ovarian cancer: an immunohistochemical study BMC Cancer 2008 8, article no. 335
4. Gmez-Raposo C., Mendiola M., Barriuso J., Casado E., Hardisson D., Redondo A., Angiogenesis and ovarian cancer Clinical Translational Oncology 2009 11 9 564 571
5. Jiang H., Feng Y., Hypoxia-inducible factor 1 (HIF-1 ) correlated with tumor growth and apoptosis in ovarian cancer International Journal of Gynecological Cancer 2006 16 supplement 1 405 412
6. Brown J. M., Wilson W. R., Exploiting tumour hypoxia in cancer treatment Nature Reviews Cancer 2004 4 6 437 447
7. Giaccia A., Siim B. G., Johnson R. S., HIF-1 as a target for drug development Nature Reviews Drug Discovery 2003 2 10 803 811
8. Powis G., Kirkpatrick L., Hypoxia inducible factor-1 as a cancer drug target Molecular Cancer Therapeutics 2004 3 5 647 654
9. Semenza G. L., Targeting HIF-1 for cancer therapy Nature Reviews Cancer 2003 3 10 721 732
10. Welsh S. J., Powis G., Hypoxia inducible factor as a cancer drug target Current Cancer Drug Targets 2003 3 6 391 405
11. Kong D., Park E. J., Stephen A. G., Calvani M., Cardellina J. H., Monks A., Fisher R. J., Shoemaker R. H., Melillo G., Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity Cancer Research 2005 65 19 9047 9055
12. Tan C., De Noronha R. G., Roecker A. J., Pyrzynska B., Khwaja F., Zhang Z., Zhang H., Teng Q., Nicholson A. C., Giannakakou P., Zhou W., Olson J. J., Pereira M. M., Nicolaou K. C., Van Meir E. G., Identification of a novel small-molecule inhibitor of the hypoxia-inducible factor 1 pathway Cancer Research 2005 65 2 605 612
13. Welsh S., Williams R., Kirkpatrick L., Paine-Murrieta G., Powis G., Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1 Molecular Cancer Therapeutics 2004 3 3 233 244
14. Drummond D. C., Noble C. O., Kirpotin D. B., Guo Z., Scott G. K., Benz C. C., Clinical development of histone deacetylase inhibitors as anticancer agents Annual Review of Pharmacology and Toxicology 2005 45 495 528
15. Johnstone R. W., Licht J. D., Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 2003 4 1 13 18
16. Marks P. A., Richon V. M., Breslow R., Rifkind R. A., Histone deacetylase inhibitors as new cancer drugs Current Opinion in Oncology 2001 13 6 477 483
17. Fath D. M., Kong X., Liang D., Lin Z., Chou A., Jiang Y., Fang J., Caro J., Sang N., Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF- Journal of Biological Chemistry 2006 281 19 13612 13619
18. Kong X., Lin Z., Liang D., Fath D., Sang N., Caro J., Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1 Molecular and Cellular Biology 2006 26 6 2019 2028
19. Ahringer J., NuRD and SIN3: histone deacetylase complexes in development Trends in Genetics 2000 16 8 351 356
20. Yang X.-J., Grgoire S., Class II histone deacetylases: from sequence to function, regulation, and clinical implication Molecular and Cellular Biology 2005 25 8 2873 2884
21. Yang X.-J., Seto E., Collaborative spirit of histone deacetylases in regulating chromatin structure and gene expression Current Opinion in Genetics and Development 2003 13 2 143 153
22. Choudhary C., Kumar C., Gnad F., Nielsen M. L., Rehman M., Walther T. C., Olsen J. V., Mann M., Lysine acetylation targets protein complexes and co-regulates major cellular functions Science 2009 325 5942 834 840
23. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., Rocha K., Kumaraswamy S., Boyapalle S., Atadja P., Seto E., Bhalla K., Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors Journal of Biological Chemistry 2005 280 29 26729 26734
24. Marks P. A., Dokmanovic M., Histone deacetylase inhibitors: discovery and development as anticancer agents Expert Opinion on Investigational Drugs 2005 14 12 1497 1511
25. Blander G., Guarente L., The Sir2 family of protein deacetylases Annual Review of Biochemistry 2004 73 417 435
26. Goodson M., Jonas B. A., Privalsky M. A., Corepressors: custom tailoring and alterations while you wait Nuclear Receptor Signal 2005 3, article no. e003
27. Rosenfeld M. G., Lunyak V. V., Glass C. K., Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response Genes and Development 2006 20 11 1405 1428
28. Joseph J., Mudduluru G., Antony S., Vashistha S., Ajitkumar P., Somasundaram K., Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB Oncogene 2004 23 37 6304 6315
29. Rascle A., Johnston J. A., Amati B., Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5 Molecular and Cellular Biology 2003 23 12 4162 4173
30. Ikenoue T., Inoki K., Zhao B., Guan K.-L., PTEN acetylation modulates its interaction with PDZ domain Cancer Research 2008 68 17 6908 6912
31. Hasselgren P.-O., Ubiquitination, phosphorylation, and acetylationtriple threat in muscle wasting Journal of Cellular Physiology 2007 213 3 679 689
32. Chen B., Cepko C. L., HDAC4 regulates neuronal survival in normal and diseased retinas Science 2009 323 5911 256 259
33. Miska E. A., Langley E., Wolf D., Karlsson C., Pines J., Kouzarides T., Differential localization of HDAC4 orchestrates muscle differentiation Nucleic Acids Research 2001 29 16 3439 3447
34. Vega R. B., Matsuda K., Oh J., Barbosa A. C., Yang X., Meadows E., McAnally J., Pomajzl C., Shelton J. M., Richardson J. A., Karsenty G., Olson E. N., Histone deacetylase 4 controls chondrocyte hypertrophy during skeletogenesis Cell 2004 119 4 555 566
35. Wang A. H., Bertos N. R., Vezmar M., Pelletier N., Crosato M., Heng H. H., Th'ng J., Han J., Yang X.-J., HDAC4, a human histone deacetylase related to yeast HDA1, is a transcriptional corepressor Molecular and Cellular Biology 1999 19 11 7816 7827
36. Huang E. Y., Zhang J., Miska E. A., Guenther M. G., Kouzarides T., Lazar M. A., Nuclear receptor corepressors partner with class II histone deacetylases in a Sin3-independent repression pathway Genes and Development 2000 14 1 45 54
37. Vega R. B., Harrison B. C., Meadows E., Roberts C. R., Papst P. J., Olson E. N., McKinsey T. A., Protein kinases C and D mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5 Molecular and Cellular Biology 2004 24 19 8374 8385
38. Lemercier C., Verdel A., Galloo B., Curtet S., Brocard M.-P., Khochbin S., mHDA1/HDAC5 histone deacetylase interacts with and represses MEF2A transcriptional activity Journal of Biological Chemistry 2000 275 20 15594 15599
39. Kovacs J. J., Murphy P. J. M., Gaillard S., Zhao X., Wu J.-T., Nicchitta C. V., Yoshida M., Toft D. O., Pratt W. B., Yao T.-P., HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor Molecular Cell 2005 18 5 601 607
40. Haggarty S. J., Koeller K. M., Wong J. C., Grozinger C. M., Schreiber S. L., Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation Proceedings of the National Academy of Sciences of the United States of America 2003 100 8 4389 4394
41. Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., Yoshida M., Wang X.-F., Yao T.-P., HDAC6 is a microtubule-associated deacetylase Nature 2002 417 6887 455 458
42. Matsuyama A., Shimazu T., Sumida Y., Saito A., Yoshimatsu Y., Seigneurin-Berny D., Osada H., Komatsu Y., Nishino N., Khochbin S., Horinouchi S., Yoshida M., In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation EMBO Journal 2002 21 24 6820 6831
43. Zhang Y., Li N., Caron C., Matthias G., Hess D., Khochbin S., Matthias P., HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo EMBO Journal 2003 22 5 1168 1179
44. Rodriguez-Gonzalez A., Lin T., Ikeda A. K., Simms-Waldrip T., Fu C., Sakamoto K. M., Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation Cancer Research 2008 68 8 2557 2560
45. Nakamura Y., Ogura M., Tanaka D., Inagaki N., Localization of mouse mitochondrial SIRT proteins: shift of SIRT3 to nucleus by co-expression with SIRT5 Biochemical and Biophysical Research Communications 2008 366 1 174 179
46. Liou G.-G., Tanny J. C., Kruger R. G., Walz T., Moazed D., Assembly of the SIR complex and its regulation by O-acetyl-ADP-ribose, a product of NAD-dependent histone deacetylation Cell 2005 121 4 515 527
47. Inoue T., Hiratsuka M., Osaki M., Oshimura M., The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation Cell Cycle 2007 6 9 1011 1018
48. North B. J., Marshall B. L., Borra M. T., Denu J. M., Verdin E., The human Sir2 ortholog, SIRT2, is an NAD + -dependent tubulin deacetylase Molecular Cell 2003 11 2 437 444
49. Vaquero A., Sternglanz R., Reinberg D., NAD + -dependent deacetylation of H4 lysine 16 by class III HDACs Oncogene 2007 26 37 5505 5520
50. Kume S., Uzu T., Horiike K., Chin-Kanasaki M., Isshiki K., Araki S.-I., Sugimoto T., Haneda M., Kashiwagi A., Koya D., Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney Journal of Clinical Investigation 2010 120 4 1043 1055
51. Araki T., Sasaki Y., Milbrandt J., Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration Science 2004 305 5686 1010 1013
52. Fainzilber M., Twiss J. L., Tracking in the wldsthe hunting of the SIRT and the luring of the draper Neuron 2006 50 6 819 821
53. Villagra A., Cheng F., Wang H-W., The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance Nature Immunology 2008 10 92 100
54. Yang X.-J., Seto E., HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention Oncogene 2007 26 37 5310 5318
55. Lin Y.-Y., Lu J.-Y., Zhang J., Walter W., Dang W., Wan J., Tao S.-C., Qian J., Zhao Y., Boeke J. D., Berger S. L., Zhu H., Protein acetylation microarray reveals that NuA4 controls key metabolic target regulating gluconeogenesis Cell 2009 136 6 1073 1084
56. Kim S. C., Sprung R., Chen Y., Xu Y., Ball H., Pei J., Cheng T., Kho Y., Xiao H., Xiao L., Grishin N. V., White M., Yang X.-J., Zhao Y., Substrate and functional diversity of lysine acetylation revealed by a proteomics survey Molecular Cell 2006 23 4 607 618
57. Gregoretti I. V., Lee Y.-M., Goodson H. V., Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis Journal of Molecular Biology 2004 338 1 17 31
58. De Ruijter A. J. M., Van Gennip A. H., Caron H. N., Kemp S., Van Kuilenburg A. B. P., Histone deacetylases (HDACs): characterization of the classical HDAC family Biochemical Journal 2003 370 3 737 749
59. Guardiola A. R., Yao T.-P., Molecular cloning and characterization of a novel histone deacetylase HDAC10 Journal of Biological Chemistry 2002 277 5 3350 3356
60. Kao H.-Y., Lee C.-H., Komarov A., Han C. C., Evans R. M., Isolation and characterization of mammalian HDAC10, a novel histone deacetylase Journal of Biological Chemistry 2002 277 1 187 193
61. Gao L., Cueto M. A., Asselbergs F., Atadja P., Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family Journal of Biological Chemistry 2002 277 28 25748 25755
62. Bolden J. E., Peart M. J., Johnstone R. W., Anticancer activities of histone deacetylase inhibitors Nature Reviews Drug Discovery 2006 5 9 769 784
63. Marks P. A., Breslow R., Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug Nature Biotechnology 2007 25 1 84 90
64. Greshock T. J., Johns D. M., Noguchi Y., Williams R. M., Improved total synthesis of the potent HDAC inhibitor FK228 (FR-901228) Organic Letters 2008 10 4 613 616
65. Taghiyev A. F., Guseva N. V., Sturm M. T., Rokhlin O. W., Cohen M. B., Trichostatin a (TSA) sensitizes the human prostatic cancer cell line DU145 to death receptor ligands treatment Cancer Biology and Therapy 2005 4 4 382 390
66. Vigushin D. M., Ali S., Pace P. E., Mirsaidi N., Ito K., Adcock I., Coombes R. C., Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo Clinical Cancer Research 2001 7 4 971 976
67. Lucas D. M., Alinari L., West D. A., Davis M. E., Edwards R. B., Johnson A. J., Blum K. A., Hofmeister C. C., Freitas M. A., Parthun M. R., Wang D., Lehman A., Zhang X., Jarjoura D., Kulp S. K., Croce C. M., Grever M. R., Chen C. S., Baiocchi R. A., Byrd J. C., The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo PLoS One 2010 5 6, article no. e10941
68. Lai C.-J., Bao R., Tao X., Wang J., Atoyan R., Qu H., Wang D.-G., Yin L., Samson M., Forrester J., Zifcak B., Xu G.-X., DellaRocca S., Zhai H.-X., Cai X., Munger W. E., Keegan M., Pepicelli C. V., Qian C., CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity Cancer Research 2010 70 9 3647 3656
69. Semenza G. L., Regulation of mammalian O2 homeostasis by hypoxia-inducible factor 1 Annual Review of Cell and Developmental Biology 1999 15 551 578
70. Semenza G. L., Expression of hypoxia-inducible factor 1: mechanisms and consequences Biochemical Pharmacology 2000 59 1 47 53
71. Hu C.-J., Sataur A., Wang L., Chen H., Simon M. C., The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1 and HIF-2 Molecular Biology of the Cell 2007 18 11 4528 4542
72. Hu C.-J., Wang L.-Y., Chodosh L. A., Keith B., Simon M. C., Differential roles of hypoxia-inducible factor 1 (HIF-1 ) and HIF-2 in hypoxic gene regulation Molecular and Cellular Biology 2003 23 24 9361 9374
73. Carroll V. A., Ashcroft M., Role of hypoxia-inducible factor (HIF)-1 versus HIF-2 in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway Cancer Research 2006 66 12 6264 6270
74. Kaelin W. G. Jr., The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma Clinical Cancer Research 2007 13 2 680s 684s
75. Liao D., Johnson R. S., Hypoxia: a key regulator of angiogenesis in cancer Cancer and Metastasis Reviews 2007 26 2 281 290
76. Bos R., Van Diest P. J., De Jong J. S., Van Der Groep P., Van Der Valk P., Van Der Wall E., Hypoxia-inducible factor-1 is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer Histopathology 2005 46 1 31 36
77. Calvani M., Rapisarda A., Uranchimeg B., Shoemaker R. H., Melillo G., Hypoxic induction of an HIF-1 -dependent bFGF autocrine loop drives angiogenesis in human endothelial cells Blood 2006 107 7 2705 2712
78. Kaelin W. G. Jr., The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing Biochemical and Biophysical Research Communications 2005 338 1 627 628
79. Lando D., Gorman J. J., Whitelaw M. L., Peet D. J., Oxygen-dependent regulation of hypoxia-inducible factors by prolyl and asparaginyl hydroxylation European Journal of Biochemistry 2003 270 5 781 790
80. Semenza G. L., Hydroxylation of HIF-1: oxygen sensing at the molecular level Physiology 2004 19 4 176 182
81. Huang L. E., Gu J., Schau M., Bunn H. F., Regulation of hypoxia-inducible factor 1 is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway Proceedings of the National Academy of Sciences of the United States of America 1998 95 14 7987 7992
82. Salceda S., Caro J., Hypoxia-inducible factor 1 (HIF-1 ) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes Journal of Biological Chemistry 1997 272 36 22642 22647
83. Arany Z., Huang L. E., Eckner R., Bhattacharya S., Jiang C., Goldberg M. A., Bunn H. F., Livingston D. M., An essential role for p300/CBP in the cellular response to hypoxia Proceedings of the National Academy of Sciences of the United States of America 1996 93 23 12969 12973
84. Carrero P., Okamoto K., Coumailleau P., O'Brien S. A., Tanaka H., Poellinger L., Redox-regulated recruitment of the transcriptional coactivators CREB-binding protein and SRC-1 to hypoxia, inducible factor 1 Molecular and Cellular Biology 2000 20 1 402 415
85. Lando D., Peet D. J., Whelan D. A., Gorman J. J., Whitelaw M. L., Asparagine hydroxylation of the HIF transactivation domain: a hypoxic switch Science 2002 295 5556 858 861
86. Sang N., Fang J., Srinivas V., Leshchinsky I., Caro J., Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP Molecular and Cellular Biology 2002 22 9 2984 2992
87. Paddenberg R., Goldenberg A., Faulhammer P., Braun-Dullaeus R. C., Kummer W., Mitochondrial complex II is essential for hypoxia-induced ROS generation and vasoconstriction in the pulmonary vasculature Advances in Experimental Medicine and Biology 2002 536 163 169
88. Guzy R. D., Hoyos B., Robin E., Chen H., Liu L., Mansfield K. D., Simon M. C., Hammerling U., Schumacker P. T., Mitochondrial complex III is required for hypoxia-induced ROS production and cellular oxygen sensing Cell Metabolism 2005 1 6 401 408
89. Meng M., Chen S., Lao T., Liang D., Sang N., Nitrogen anabolism underlies the importance of glutaminolysis in proliferating cells Cell Cycle 2010 9 19 3921 3932
90. Semenza G. L., Intratumoral hypoxia, radiation resistance, and HIF-1 Cancer Cell 2004 5 5 405 406
91. Semenza G. L., Development of novel therapeutic strategies that target HIF-1 Expert Opinion on Therapeutic Targets 2006 10 2 267 280
92. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.-M., Simons J. W., Semenza G. L., Modulation of hypoxia-inducible factor 1 expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics Cancer Research 2000 60 6 1541 1545
93. Vaupel P., Hckel M., Mayer A., Detection and characterization of tumor hypoxia using pO 2 histography Antioxidants and Redox Signaling 2007 9 8 1221 1235
94. Ryan H. E., Lo J., Johnson R. S., HIF-1 is required for solid tumor formation and embryonic vascularization EMBO Journal 1998 17 11 3005 3015
95. Ryan H. E., Poloni M., McNulty W., Elson D., Gassmann M., Arbeit J. M., Johnson R. S., Hypoxia-inducible factor-1 is a positive factor in solid tumor growth Cancer Research 2000 60 15 4010 4015
96. Hirota K., Semenza G. L., Regulation of angiogenesis by hypoxia-inducible factor 1 Critical Reviews in Oncology/Hematology 2006 59 1 15 26
97. Bouzin C., Feron O., Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery Drug Resistance Updates 2007 10 3 109 120
98. Licht A. H., Mller-Holtkamp F., Flamme I., Breier G., Inhibition of hypoxia-inducible factor activity in endothelial cells disrupts embryonic cardiovascular development Blood 2006 107 2 584 590
99. Lfstedt T., Fredlund E., Holmquist-Mengelbier L., Pietras A., Ovenberger M., Poellinger L., Phlman S., Hypoxia inducible factor-2 in cancer Cell Cycle 2007 6 8 919 926
100. An W. G., Kanekal M., Simon M. C., Maltepe E., Blagosklonny M. V., Neckers L. M., Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha Nature 1998 392 6674 405 408
101. Blagosklonny M. V., An W. G., Romanova L. Y., Trepel J., Fojo T., Neckers L., p53 inhibits hypoxia-inducible factor-stimulated transcription Journal of Biological Chemistry 1998 273 20 11995 11998
102. Isaacs J. S., Jung Y. J., Mole D. R., Lee S., Torres-Cabala C., Chung Y.-L., Merino M., Trepel J., Zbar B., Toro J., Ratcliffe P. J., Linehan W. M., Neckers L., HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability Cancer Cell 2005 8 2 143 153
103. Ravi R., Mookerjee B., Bhujwalla Z. M., Sutter C. H., Artemov D., Zeng Q., Dillehay L. E., Madan A., Semenza G. L., Bedi A., Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1 Genes and Development 2000 14 1 34 44
104. Sang N., Stiehl D. P., Bohensky J., Leshchinsky I., Srinivas V., Caro J., MAPK signaling up-regulates the activity of hypoxia-inducible factors by its effects on p300 Journal of Biological Chemistry 2003 278 16 14013 14019
105. Selak M. A., Armour S. M., MacKenzie E. D., Boulahbel H., Watson D. G., Mansfield K. D., Pan Y., Simon M. C., Thompson C. B., Gottlieb E., Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF- prolyl hydroxylase Cancer Cell 2005 7 1 77 85
106. Zundel W., Schindler C., Haas-Kogan D., Koong A., Kaper F., Chen E., Gottschalk A. R., Ryan H. E., Johnson R. S., Jefferson A. B., Stokoe D., Giaccia A. J., Loss of PTEN facilitates HIF-1-mediated gene expression Genes and Development 2000 14 4 391 396
107. Neckers L., Neckers K., Heat-shock protein 90 inhibitors as novel cancer chemotherapeuticsan update Expert Opinion on Emerging Drugs 2005 10 1 137 149
108. Miyata Y., Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents Current Pharmaceutical Design 2005 11 9 1131 1138
109. Bazzaro M., Lee M. K., Zoso A., Stirling W. L. H., Santillan A., Shih I.-M., Roden R. B. S., Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis Cancer Research 2006 66 7 3754 3763
110. Ishii Y., Waxman S., Germain D., Targeting the ubiquitin-proteasome pathway in cancer therapy Anti-Cancer Agents in Medicinal Chemistry 2007 7 3 359 365
111. Joazeiro C. A. P., Anderson K. C., Hunter T., Proteasome inhibitor drugs on the rise Cancer Research 2006 66 16 7840 7842
112. Sunwoo J. B., Chen Z., Dong G., Yeh N., Bancroft C. C., Sausville E., Adams J., Elliott P., Van Waes C., Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor- B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma Clinical Cancer Research 2001 7 5 1419 1428
113. Escuin D., Kline E. R., Giannakakou P., Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1 accumulation and activity by disrupting microtubule function Cancer Research 2005 65 19 9021 9028
114. Mabjeesh N. J., Escuin D., LaVallee T. M., Pribluda V. S., Swartz G. M., Johnson M. S., Willard M. T., Zhong H., Simons J. W., Giannakakou P., 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF Cancer Cell 2003 3 4 363 375
115. Newcomb E. W., Lukyanov Y., Schnee T., Ali M. A., Lan L., Zagzag D., Noscapine inhibits hypoxia-mediated HIF-1alpha expression andangiogenesis in vitro: a novel function for an old drug International Journal of Oncology 2006 28 5 1121 1130
116. Qian D. Z., Kachhap S. K., Collis S. J., Verheul H. M.W., Carducci M. A., Atadja P., Pili R., Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 Cancer Research 2006 66 17 8814 8821
117. Kato H., Tamamizu-Kato S., Shibasaki F., Histone deacetylase 7 associates with hypoxia-inducible factor 1 and increases transcriptional activity Journal of Biological Chemistry 2004 279 40 41966 41974
118. Kim M. S., Kwon H. J., Lee Y. M., Baek J. H., Jang J.-E., Lee S.-W., Moon E.-J., Kim H.-S., Lee S.-K., Chung H. Y., Kim C. W., Kim K.-W., Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes Nature Medicine 2001 7 4 437 443
119. Maltepe E., Krampitz G. W., Okazaki K. M., Red-Horse K., Mak W., Simon M. C., Fisher S. J., Hypoxia-inducible factor-dependent histone deacetylase activity determines stem cell fate in the placenta Development 2005 132 15 3393 3403
120. Lee Y. M., Kim S.-H., Kim H.-S., Son M. J., Nakajima H., Kwon H. J., Kim K.-W., Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1 activity Biochemical and Biophysical Research Communications 2003 300 1 241 246
121. Sasakawa Y., Naoe Y., Noto T., Inoue T., Sasakawa T., Matsuo M., Manda T., Mutoh S., Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors Biochemical Pharmacology 2003 66 6 897 906
122. Zgouras D., Wchtershuser A., Frings D., Stein J., Butyrate impairs intestinal tumor cell-induced angiogenesis by inhibiting HIF- 1 nuclear translocation Biochemical and Biophysical Research Communications 2003 300 4 832 838
123. Inoue T., Hiratsuka M., Osaki M., Oshimura M., The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation Cell Cycle 2007 6 9 1011 1018
124. Jeong J.-W., Bae M.-K., Ahn M.-Y., Kim S.-H., Sohn T.-K., Bae M.-H., Yoo M.-A., Song E. J., Lee K.-J., Kim K.-W., Regulation and destabilization of HIF-1 by ARD1-mediated acetylation Cell 2002 111 5 709 720
125. Li Y., Yuan Z., Liu B., Sailhamer E. A., Shults C., Velmahos G. C., Demoya M., Alam H. B., Prevention of hypoxia-induced neuronal apoptosis through histone deacetylase inhibition Journal of Trauma 2008 64 4 863 870
126. Manabe H., Nasu Y., Komiyama T., Furumatsu T., Kitamura A., Miyazawa S., Ninomiya Y., Ozaki T., Asahara H., Nishida K., Inhibition of histone deacetylase down-regulates the expression of hypoxia-induced vascular endothelial growth factor by rheumatoid synovial fibroblasts Inflammation Research 2008 57 1 4 10
127. Kim S. H., Kim K. W., Jeong J. W., Inhibition of hypoxia-induced angiogenesis by sodium butyrate, a histone deacetylase inhibitor, through hypoxia-inducible factor-1alpha suppression Oncology Report 2007 17 4 793 797
128. Demidenko Z. N., Rapisarda A. M., Garayoa M., Giannakakou P., Melillo G., Blagosklonny M. V., Accumulation of hypoxia-inducible factor-1 is limited by transcription-dependent depletion Oncogene 2005 24 30 4829 4838
129. Kasper L. H., Boussouar F., Boyd K., Xu W., Biesen M., Rehg J., Baudino T. A., Cleveland J. L., Brindle P. K., Two transactivation mechanisms cooperate for the bulk of HIF-1-responsive gene expression EMBO Journal 2005 24 22 3846 3858
130. Kasper L. H., Brindle P. K., Mammalian gene expression program resiliency: the roles of multiple coactivator mechanisms in hypoxia-responsive transcription Cell Cycle 2006 5 2 142 146
131. Stiehl D. P., Fath D. M., Liang D., Jiang Y., Sang N., Histone deacetylase inhibitors synergize p300 autoacetylation that regulates its transactivation activity and complex formation Cancer Research 2007 67 5 2256 2264
132. Hansson M. L., Popko-cibor A. E., Saint Just Ribeiro M., Dancy B. M., Lindberg M. J., Cole P. A., Wallberg A. E., The transcriptional coactivator MAML1 regulates p300 autoacetylation and HAT activity Nucleic Acids Research 2009 37 9 2996 3006
133. Black J. C., Mosley A., Kitada T., Washburn M., Carey M., The SIRT2 deacetylase regulates autoacetylation of p300 Molecular Cell 2008 32 3 449 455
134. Simone C., Stiegler P., Forcales S.-V., Bagella L., De Luca A., Sartorelli V., Giordano A., Puri P. L., Deacetylase recruitment by the C/H3 domain of the acetyltransferase p300 Oncogene 2004 23 12 2177 2187
135. Xiao H., Hasegawa T., Isobe K.-I., p300 Collaborates with Sp1 and Sp3 in p21(waf1/cip1) promoter activation induced by histone deacetylase inhibitor Journal of Biological Chemistry 2000 275 2 1371 1376
136. Ruas J. L., Berchner-Pfannschmidt U., Malik S., Gradin K., Fandrey J., Roeder R. G., Pereira T., Poellinger L., Complex regulation of the transactivation function of hypoxia-inducible factor-1 by direct interaction with two distinct domains of the creb-binding protein/p300 Journal of Biological Chemistry 2010 285 4 2601 2609
137. Liang D., Kong X., Sang N., Effects of histone deacetylase inhibitors on HIF-1 Cell Cycle 2006 5 21 2430 2435
138. Sadoul K., Boyault C., Pabion M., Khochbin S., Regulation of protein turnover by acetyltransferases and deacetylases Biochimie 2008 90 2 306 312
139. Caron C., Boyault C., Khochbin S., Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability BioEssays 2005 27 4 408 415
140. Arnesen T., Kong X., Evjenth R., Gromyko D., Varhaug J. E., Lin Z., Sang N., Caro J., Lillehaug J. R., Interaction between HIF-1 (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1 FEBS Letters 2005 579 28 6428 6432
141. Bilton R., Mazure N., Trottier E., Hattab M., Dry M.-A., Richard D. E., Pouyssgur J., Brahimi-Horn M. C., Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1 and is not induced by hypoxia or HIF Journal of Biological Chemistry 2005 280 35 31132 31140
142. Fisher T. S., Des Etages S., Hayes L., Crimin K., Li B., Analysis of ARD1 function in hypoxia response using retroviral RNA interference Journal of Biological Chemistry 2005 280 18 17749 17757
143. Murray-Rust T. A., Oldham N. J., Hewitson K. S., Schofield C. J., Purified recombinant hARD1 does not catalyse acetylation of Lys 532 of HIF-1 fragments in vitro FEBS Letters 2006 580 8 1911 1918
144. Kim S.-H., Park J. A., Kim J. H., Lee J.-W., Seo J. H., Jung B.-K., Chun K.-H., Jeong J.-W., Bae M.-K., Kim K.-W., Characterization of ARD1 variants in mammalian cells Biochemical and Biophysical Research Communications 2006 340 2 422 427
145. Sanchez-Puig N., Fersht A. R., Characterization of the native and fibrillar conformation of the human nalpha-acetyltransferase ard1 Protein Science 2006 15 8 1968 1976
146. Seo J. H., Cha J.-H., Park J.-H., Jeong C.-H., Park Z.-Y., Lee H.-S., Oh S. H., Kang J.-H., Suh S. W., Kim K. H., Ha J. Y., Han S. H., Kim S.-H., Lee J.-W., Park J. A., Jeong J.-W., Lee K.-J., Oh G. T., Lee M.-N., Kwon S. W., Lee S.-K., Chun K.-H., Lee S.-J., Kim K.-W., Arrest defective 1 autoacetylation is a critical step in its ability to stimulate cancer cell proliferation Cancer Research 2010 70 11 4422 4432
147. Chang C.-C., Lin M.-T., Lin B.-R., Jeng Y.-M., Chen S.-T., Chu C.-Y., Chen R. J., Chang K.-J., Yang P.-C., Kuo M.-L., Effect of connective tissue growth factor on hypoxia-inducible factor 1 degradation and tumor angiogenesis Journal of the National Cancer Institute 2006 98 14 984 995
148. Lin S., Tsai S.-C., Lee C.-C., Wang B.-W., Liou J.-Y., Shyu K.-G., Berberine inhibits HIF-1 expression via enhanced proteolysis Molecular Pharmacology 2004 66 3 612 619
149. Xenaki G., Ontikatze T., Rajendran R., Stratford I. J., Dive C., Krstic-Demonacos M., Demonacos C., PCAF is an HIF-1 cofactor that regulates p53 transcriptional activity in hypoxia Oncogene 2008 27 44 5785 5796
150. Dioum E. M., Chen R., Alexander M. S., Zhang Q., Hogg R. T., Gerard R. D., Garcia J. A., Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1 Science 2009 324 5932 1289 1293
151. Luo W., Zhong J., Chang R., Hu H., Pandey A., Semenza G. L., Hsp70 and CHIP selectively mediate ubiquitination and degradation of hypoxia-inducible factor (HIF)-1 but not HIF-2 Journal of Biological Chemistry 2010 285 6 3651 3663
152. Zeng G.-C., Ozer H. L., Hand R., Further characterization of the phenotype of ts20, a DNA(ts) mutant of BALB/3T3 cells Experimental Cell Research 1985 160 1 184 196
153. Buchner J., Hsp90 and Co.a holding for folding Trends in Biochemical Sciences 1999 24 4 136 141
154. Chiosis G., Lopes E. C., Solit D., Heat shock protein-90 inhibitors: a
155. Goetz M. P., Toft D. O., Ames M. M., Erlichman C., The Hsp90 chaperone complex as a novel target for cancer therapy Annals of Oncology 2003 14 8 1169 1176
156. Ai J., Wang Y., Dar J. A., Liu J., Liu L., Nelson J. B., Wang Z., HDAC6 regulates androgen receptor hypersensitivity and nuclear localization via modulating Hsp90 acetylation in castration-resistant prostate cancer Molecular Endocrinology 2009 23 12 1963 1972
157. Kekatpure V. D., Dannenberg A. J., Subbaramaiah K., HDAC6 modulates Hsp90 chaperone activity and regulates activation of aryl hydrocarbon receptor signaling Journal of Biological Chemistry 2009 284 12 7436 7445
158. Basak S., Pookot D., Noonan E. J., Dahiya R., Genistein down-regulates androgen receptor by modulating HDAC6-Hsp90 chaperone function Molecular Cancer Therapeutics 2008 7 10 3195 3202
159. Rao R., Fiskus W., Yang Y., Lee P., Joshi R., Fernandez P., Mandawat A., Atadja P., Bradner J. E., Bhalla K., HDAC6 inhibition enhances 17-AAG mediated abrogation of hsp90 chaperone function in human leukemia cells Blood 2008 112 5 1886 1893
160. Kovacs J. J., Murphy P. J. M., Gaillard S., Zhao X., Wu J.-T., Nicchitta C. V., Yoshida M., Toft D. O., Pratt W. B., Yao T.-P., HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor Molecular Cell 2005 18 5 601 607
161. L'Hernault S. W., Rosenbaum J. L., Chlamydomonas alpha-tubulin is posttranslationally modified by acetylation on the epsilon-amino group of a lysine Biochemistry 1985 24 2 473 478
162. Maruta H., Greer K., Rosenbaum J. L., The acetylation of alpha-tubulin and its relationship to the assembly and disassembly of microtubules Journal of Cell Biology 1986 103 2 571 579
163. Tran A. D.-A., Marmo T. P., Salam A. A., Che S., Finkelstein E., Kabarriti R., Xenias H. S., Mazitschek R., Hubbert C., Kawaguchi Y., Sheetz M. P., Yao T.-P., Bulinski J. C., HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions Journal of Cell Science 2007 120 8 1469 1479
164. Boyault C., Sadoul K., Pabion M., Khochbin S., HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination Oncogene 2007 26 37 5468 5476
165. Thomas S. L., Zhong D., Zhou W., Malik S., Liotta D., Snyder J. P., Hamel E., Giannakakou P., EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1 Cell Cycle 2008 7 15 2409 2417
166. Lim J. H., Lee Y. M., Chun Y. S., Chen J., Kim J. E., Park J. W., Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha Molecular cell 2010 38 6 864 878
167. Zhao S., Xu W., Jiang W., Yu W., Lin Y., Zhang T., Yao J., Zhou L., Zeng Y., Li H., Li Y., Shi J., An W., Hancock S. M., He F., Qin L., Chin J., Yang P., Chen X., Lei Q., Xiong Y., Guan K.-L., Regulation of cellular metabolism by protein lysine acetylation Science 2010 327 5968 1000 1004
168. Granger A., Abdullah I., Huebner F., Stout A., Wang T., Huebner T., Epstein J. A., Gruber P. J., Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice FASEB Journal 2008 22 10 3549 3560
169. Colussi C., Illi B., Rosati J., Spallotta F., Farsetti A., Grasselli A., Mai A., Capogrossi M. C., Gaetano C., Histone deacetylase inhibitors: keeping momentum for neuromuscular and cardiovascular diseases treatment Pharmacological Research 2010 62 1 3 10
170. Colussi C., Berni R., Rosati J., Straino S., Vitale S., Spallotta F., Baruffi S., Bocchi L., Delucchi F., Rossi S., Savi M., Rotili D., Quaini F., MacChi E., Stilli D., Musso E., Mai A., Gaetano C., Capogrossi M. C., The histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces cardiac arrhythmias in dystrophic mice Cardiovascular Research 2010 87 1 73 82